Chen Tung
Cardiovascular Disease · Frederick, MDNPI 1588667976
Payments from drug & device makers
Across 207 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$561
- Johnson & Johnson$423
- Amgen$360
- AstraZeneca$313
- Novartis$289
- Esperion Therapeutics, Inc.$245
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,721100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 28 | $561 |
| Johnson & Johnson | 29 | $423 |
| Amgen | 21 | $360 |
| AstraZeneca | 14 | $313 |
| Novartis | 17 | $289 |
| Esperion Therapeutics, Inc. | 13 | $245 |
| Abbott | 6 | $209 |
| Arbor Pharmaceuticals, Inc. | 10 | $162 |
| Sanofi-aventis U.S. LLC | 11 | $148 |
| Boehringer Ingelheim | 7 | $124 |
| Medtronic | 4 | $117 |
| E.r. Squibb & Sons, L.L.C. | 6 | $90 |
| Pfizer | 6 | $81 |
| Novo Nordisk | 4 | $73 |
| Boston Scientific | 3 | $70 |
| Regeneron Healthcare Solutions, Inc. | 5 | $61 |
| Merck | 4 | $58 |
| Alnylam Pharmaceuticals Inc. | 2 | $50 |
| Edwards Lifesciences | 3 | $49 |
| Lundbeck LLC | 3 | $47 |
| Philips North America LLC | 1 | $43 |
| Bardy Diagnostics, Inc. | 2 | $34 |
| Gilead | 2 | $30 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Sanofi | 1 | $16 |
| GE HealthCare | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$3,731 in reported general payments places this provider in the 60th percentile of 507 cardiovascular disease providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 25 | $27,580 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 16 | $817 |
| Metoprolol Succinate | 27 | $611 |
| Rosuvastatin Calcium | 18 | $482 |
| Amlodipine Besylate | 24 | $233 |
| Losartan Potassium | 24 | $201 |
| Ramipril | 11 | $87 |
| Atorvastatin Calcium | 15 | $56 |
| Hydrochlorothiazide | 21 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $81 | $27,58025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Frederick
- Christopher DefilippiBaltimore$9.2M
- Thorsten LeuckerBaltimore$7.1M
- Joao LimaBaltimore$5.6M
- Jeffrey ColeBaltimore$4.8M
- Carlos InceBaltimore$3M
- Paul GurbelBaltimore$2.6M
- Navin KapurBaltimore$1.8M
- Vineet VenugopalLanham$1.5M
- Robert WeissBaltimore$1.4M
- Stephen GottliebBaltimore$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.